Milestone Pharmaceuticals Inc. Research and Development Expense
Milestone Pharmaceuticals Inc. (MIST) reported Research and Development Expense of $3.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. research and development expense for the quarter ending 2026-06-30 was $3.51M, a 4.36% decline year-over-year.
- Milestone Pharmaceuticals Inc. research and development expense for the quarter ending 2026-03-31 was $3.25M, a 34.69% decline year-over-year.
- Milestone Pharmaceuticals Inc. research and development expense for the quarter ending 2025-12-31 was $5.52M, a 40.13% increase year-over-year.
- Milestone Pharmaceuticals Inc. research and development expense for the quarter ending 2025-09-30 was $3.94M, a 0.58% decline year-over-year.
- Milestone Pharmaceuticals Inc. research and development expense for fiscal 2025 was $18.11M, a 26.13% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. research and development expense for fiscal 2024 was $14.36M, a 53.76% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. research and development expense for fiscal 2023 was $31.05M, a 22.04% decline from fiscal 2022.
- Milestone Pharmaceuticals Inc. research and development expense for fiscal 2022 was $39.83M, a 2.99% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51M 10-Q · filed 2026-08-12 | $6.76M 10-Q · filed 2026-08-12 | $12.28M derived: sum of 3 quarters · filed 2026-08-12 | $16.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $3.25M 10-Q · filed 2026-05-13 | $8.77M derived: sum of 2 quarters · filed 2026-05-13 | $12.71M derived: sum of 3 quarters · filed 2026-05-13 | $16.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $9.46M derived: sum of 2 quarters · filed 2026-03-20 | $13.13M derived: sum of 3 quarters · filed 2026-08-12 | $18.11M 10-K · filed 2026-03-20 |
| 2025-09-30 | $3.94M 10-Q · filed 2025-11-12 | $7.61M derived: sum of 2 quarters · filed 2026-08-12 | $12.59M 10-Q · filed 2025-11-12 | $16.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.67M 10-Q · filed 2026-08-12 | $8.65M 10-Q · filed 2026-08-12 | $12.59M derived: sum of 3 quarters · filed 2026-08-12 | $16.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $4.98M 10-Q · filed 2026-05-13 | $8.92M derived: sum of 2 quarters · filed 2026-05-13 | $12.88M derived: sum of 3 quarters · filed 2026-05-13 | $15.70M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $7.90M derived: sum of 2 quarters · filed 2026-03-20 | $10.72M derived: sum of 3 quarters · filed 2026-03-20 | $14.36M 10-K · filed 2026-03-20 |
| 2024-09-30 | $3.96M 10-Q · filed 2025-11-12 | $6.78M derived: sum of 2 quarters · filed 2025-11-12 | $10.42M 10-Q · filed 2025-11-12 | $15.87M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.81M 10-Q · filed 2025-08-12 | $6.45M 10-Q · filed 2025-08-12 | $11.91M derived: sum of 3 quarters · filed 2025-08-12 | $18.63M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.64M 10-Q · filed 2025-05-14 | $9.09M derived: sum of 2 quarters · filed 2025-05-14 | $15.81M derived: sum of 3 quarters · filed 2025-05-14 | $24.43M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.17M derived: sum of 2 quarters · filed 2025-03-13 | $20.80M derived: sum of 3 quarters · filed 2025-03-13 | $31.05M 10-K · filed 2025-03-13 |
| 2023-09-30 | $6.72M 10-Q · filed 2024-11-12 | $15.34M derived: sum of 2 quarters · filed 2024-11-12 | $25.60M 10-Q · filed 2024-11-12 | $36.18M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $8.62M 10-Q · filed 2024-08-08 | $18.88M 10-Q · filed 2024-08-08 | $29.46M derived: sum of 3 quarters · filed 2024-08-08 | $39.28M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $10.26M 10-Q · filed 2024-05-13 | $20.84M derived: sum of 2 quarters · filed 2024-05-13 | $30.66M derived: sum of 3 quarters · filed 2024-05-13 | $41.32M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $10.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $20.40M derived: sum of 2 quarters · filed 2024-03-21 | $31.06M derived: sum of 3 quarters · filed 2024-03-21 | $39.83M 10-K · filed 2024-03-21 |
| 2022-09-30 | $9.83M 10-Q · filed 2023-11-13 | $20.48M derived: sum of 2 quarters · filed 2023-11-13 | $29.25M 10-Q · filed 2023-11-13 | $40.17M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $10.66M 10-Q · filed 2023-08-10 | $19.43M 10-Q · filed 2023-08-10 | $30.34M derived: sum of 3 quarters · filed 2023-08-10 | $40.07M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $8.77M 10-Q · filed 2023-05-11 | $19.68M derived: sum of 2 quarters · filed 2023-05-11 | $29.42M derived: sum of 3 quarters · filed 2023-05-11 | $38.84M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $10.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $20.65M derived: sum of 2 quarters · filed 2023-03-29 | $30.08M derived: sum of 3 quarters · filed 2023-03-29 | $38.67M 10-K · filed 2023-03-29 |
| 2021-09-30 | $9.73M 10-Q · filed 2022-11-10 | $19.16M derived: sum of 2 quarters · filed 2022-11-10 | $27.75M 10-Q · filed 2022-11-10 | $33.52M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $9.43M 10-Q · filed 2022-08-10 | $18.02M 10-Q · filed 2022-08-10 | $23.79M derived: sum of 3 quarters · filed 2022-08-10 | $32.02M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $8.60M 10-Q · filed 2022-05-12 | $14.36M derived: sum of 2 quarters · filed 2022-05-12 | $22.59M derived: sum of 3 quarters · filed 2022-05-12 | $31.21M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $13.99M derived: sum of 2 quarters · filed 2022-03-24 | $22.62M derived: sum of 3 quarters · filed 2022-03-24 | $34.49M 10-K · filed 2022-03-24 |
| 2020-09-30 | $8.23M 10-Q · filed 2021-11-12 | $16.85M derived: sum of 2 quarters · filed 2021-11-12 | $28.72M 10-Q · filed 2021-11-12 | $42.87M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $8.62M 10-Q · filed 2021-08-11 | $20.49M 10-Q · filed 2021-08-11 | $34.64M derived: sum of 3 quarters · filed 2021-08-11 | $44.19M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $11.87M 10-Q · filed 2021-05-17 | $26.02M derived: sum of 2 quarters · filed 2021-05-17 | $35.57M derived: sum of 3 quarters · filed 2021-05-17 | $46.09M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $14.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $23.69M derived: sum of 2 quarters · filed 2021-03-29 | $34.22M derived: sum of 3 quarters · filed 2021-03-29 | $41.98M 10-K · filed 2021-03-29 |
| 2019-09-30 | $9.54M 10-Q · filed 2020-11-13 | $20.07M derived: sum of 2 quarters · filed 2020-11-13 | $27.84M 10-Q · filed 2020-11-13 | $35.13M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $10.53M 10-Q · filed 2020-08-12 | $18.29M 10-Q · filed 2020-08-12 | $25.59M derived: sum of 3 quarters · filed 2020-10-23 | $29.50M derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | $7.76M 10-Q · filed 2020-05-14 | $15.06M derived: sum of 2 quarters · filed 2020-10-23 | $18.97M derived: sum of 3 quarters · filed 2020-10-23 | $21.52M derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | $7.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $11.21M derived: sum of 2 quarters · filed 2020-10-23 | $13.76M derived: sum of 3 quarters · filed 2020-10-23 | $16.85M 10-K/A · filed 2020-10-23 |
| 2018-09-30 | $3.91M 10-Q · filed 2019-11-13 | $6.46M derived: sum of 2 quarters · filed 2019-11-13 | $9.55M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $2.55M 10-Q · filed 2019-08-13 | $5.64M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $3.09M 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |